Alteration of Respiratory Microbiota and Local Immune Response in Common Variable Immunodeficiency

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aims to establish cutting-edge approaches to study pulmonary biology in CVID and apply novel bioinformatics strategies to study complex interactions among microbes and host cells by direct sampling of the respiratory tract. The central hypothesis for this research is that antibody (Ab) deficiency in CVID alters respiratory microbiota and host interactions to drive pulmonary disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• Patients with primary antibody deficiency diagnosed by their treating physician

• Controls will not have a diagnosis of immunodeficiency of any sort

• Male and female patients will be enrolled evenly

Locations
United States
Massachusetts
Boston Medical Center
RECRUITING
Boston
Contact Information
Primary
Paul J Maglione, MD PhD
pmaglion@bu.edu
617 358 0913
Backup
Matthew S Ware, MS
msware@bu.edu
765 437 1305
Time Frame
Start Date: 2024-03-15
Estimated Completion Date: 2026-02
Participants
Target number of participants: 80
Treatments
Antibody deficient participants
Provider referred patients that have antibody deficiency.
Controls
Patients without antibody deficiency from the allergy and immunology clinic at Boston Medical Center and from healthy volunteers at the BU School of Medicine.
Related Therapeutic Areas
Sponsors
Collaborators: Takeda
Leads: Boston University

This content was sourced from clinicaltrials.gov